Comparing the current results to its competitors, Abbvie Inc reported Revenue increase in the 1 quarter 2026 by 12.43 % year on year. The sales growth was above Abbvie Inc 's competitors' average revenue growth of 10.83 %, achieved in the same quarter.
Abbvie Inc Net Income in the 1 quarter 2026 fell year on year by -45.93%, while most of its competitors have experienced a contraction in net income by -27.02 %.
Abbvie Inc 's Comment on Competition and Industry Peers
AbbVie operates in highly competitive markets, facing competition from other research-based pharmaceutical and biotechnology companies that develop proprietary pharmaceutical products, therapies, and biologics. Its immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars, and other products across various disease states. AbbVie's oncology products compete with targeted therapies, including BTK inhibitors, antibody-drug conjugates (ADCs), cell therapies, and other treatments for certain cancers. Additionally, several companies have developed and marketed products competing with Botox. Competition also arises from technological innovation, new product introductions, changes in medical practices, pricing strategies, and the substitution of generic and biosimilar products for branded pharmaceuticals, particularly those without patent protection.
March 25, 2024
The NIMML Institute (NIMML), a renowned nonprofit institute dedicated to the discovery of innovative precision medicines for autoimmune diseases, is celebrating a significant milestone. Its co-founders, Dr. Josep Bassaganya-Riera and Dr. Raquel Hontecillas, along with scientific director Dr. Andrew Leber, have been recognized for their exceptional leadership in the discovery and development of NX-13. This achievement paved the way for the recent acquisition of Landos Biopharma, Inc. (Landos) by pharmaceutical giant AbbVie, Inc. (NYSE: ABBV). The NIMML Institute s groundbreaking TITAN-X A.I.-Powered Precision Medicine Platform played a crucial role in this achievement.Groundbreaking Precision Medicine Platfor...
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
Sources:
Abbvie Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Abbvie Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
